Distributors pitch $10B settlement in opioid talks: Bloomberg

美国三大药品分销商提出100亿美元和解阿片类药物诉讼,检察长:得450亿!

2019-08-08 18:01:00 FiercePharma

本文共775个字,阅读需2分钟

In the complex tangle of opioid lawsuits against drugmakers and distributors, one big number has emerged, Bloomberg reports.  The nation’s top three drug distributors—McKesson, AmerisourceBergen and Cardinal Health—have verbally offered a $10 billion settlement with state attorneys general, according to the news service. AGs hit back with a much higher demand of $45 billion. Bloomberg cited three unnamed people familiar with the discussions in its reporting. A McKesson representative told Bloomberg “we regularly engage with the state attorneys general, but the company has made no settlement offers.” The other companies declined to comment, the news service reports.   Drugmakers and distributors face thousands of lawsuits alleging pharma companies oversold the benefits and downplayed the risks of using opioids to treat chronic pain. Plaintiffs say distributors failed to monitor suspicious orders and flooded communities with millions of pills. Together, the conduct contributed to a national opioid epidemic, the plaintiffs say. Aside from thousands of lawsuits from cities and counties, state attorneys general are conducting their own probes and lawsuits.   Importantly, the offer was reportedly made in negotiations with state attorneys general. It isn’t clear whether cities and counties would join a potential deal struck by AGs, or whether they'd pursue their own damages. Investors sent shares for the distributors down by about 6% Tuesday afternoon.  Aside from talks with AGs, plaintiffs in the lawsuits brought by cities and counties have proposed a novel “negotiating class” to help the sides reach a deal, but one expert told FiercePharma that idea isn’t helping. Perry Zinn Rowthorn, formerly a Connecticut deputy attorney general and now a partner at Shipman & Goodwin, argued that AGs are better suited to reach a deal. Then localities could join in, he said. A federal judge in Cleveland signaled support for the “negotiating class” idea on Tuesday, Legal Newsline reports. The first trial in the multidistrict litigation is set for October, but defendants have asked for a delay, citing the complexity of the litigation.  Analysts have put forth a range of estimates into potential liabilities for drugmakers and distributors, with Wells Fargo's David Maris saying the issue could cost defendants up to $100 billion.
彭博( Bloomberg )报道称,在针对制药商和分销商的一系列复杂的阿片类药物类诉讼中,出现了大量案件。 据美国最大的三家药品分销商—— McKesson 、 AmericansourcesBergen 和 Cardinal Health ——已口头提出与州总检察长达成100亿美元和解。AGs 的需求大幅增加,达到450亿美元。彭博在报道中提到了三位知情人士。 麦肯森的一位代表告诉彭博,“我们经常与州检察长接触,但该公司没有提出和解建议。”新闻服务报道称,其他公司拒绝置评。 制药商和分销商面临数千起诉讼,指控制药公司夸大效益,淡化使用阿片类药物治疗慢性疼痛的风险。原告说,经销商没有监控可疑的订单,给社区带来了数百万药丸。原告说,这些行为共同导致了全国范围内的阿片类疾病流行。除了来自城市和县的数千起诉讼外,州总检察长也在进行自己的调查和诉讼。 重要的是,据报道,该提议是在与州总检察长谈判中提出的。目前还不清楚城市和县是否会加入 AGs 达成的潜在协议,或者是否会寻求自己的损害赔偿。 投资者周二下午给分销商的股票下跌了约6%。 除了与 AGs 谈判之外,城市和县提起的诉讼中的原告还提出了一种新颖的“谈判课”,以帮助双方达成协议,但一位专家告诉 FiercePharma ,这种想法并没有帮助。Perry Zinn Rowthorn ,前康涅狄格州副总检察长,现为 Shipman & Goodwin 合伙人,认为 AGs 更适合达成交易。然后地方可以加入,他说。 据《法律新闻》报道,克利夫兰的一名联邦法官周二表示支持“谈判课”的想法。多重诉讼中的第一次审判定于10月进行,但被告以诉讼的复杂性为由要求推迟审理。 分析人士对制药商和分销商的潜在债务提出了一系列估计,富国银行的大卫·马里斯说,这一问题可能使被告损失高达1000亿美元。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文